Trind leads the investment round in Evogenom, alongside several angel investors. Evogenom provides genetic insights and science-based advice for individuals interested in enhancing their well-being. This information is accessible through Evogenom’s mobile application, available after clients complete an at-home genetic test and return it to the company. Evogenom stands out as it has developed its own genotyping chip and software for comprehensive analysis, focusing on the genetics of traits.
This funding strengthens our sales initiatives, allowing us to grow our business and solidify our market position. It also enables us to refine our products and supports our international expansion efforts. We are excited about the future and the opportunity to reach and serve an even wider audience.
Hannu Tolvanen, CEO of Evogenom
Evogenom’s innovative genetic tests can provide valuable insights into well-being, recovery, sleep, exercise, nutrition, and medication. The company is distinct for its ability to combine scientific accuracy with user-friendliness, making genetic testing accessible and understandable for everyone.
We are thrilled to invest in Evogenom, as their team has developed an outstanding product backed by their extensive industry expertise.
Kimmo Irpola, Partner at Trind
As the genetic testing market continues to grow rapidly, Evogenom is well-positioned to seize the opportunities. With an increasing number of consumers prioritizing their well-being, the demand for reliable and user-friendly health tools continues to rise. In May 2024, Evogenom’s Board of Directors appointed Antti Seppä, CEO of Docue and former CEO of Admicom, as the new Chairman of the Board.
My interest in human physiology first led me to Evogenom, where I quickly recognized its potential for international growth. After hearing about the investment round and Trind VC’s involvement, it was an easy decision to join the journey as Chairman.
Antti Seppä, Chairman of the Board at Evogenom
Are you building a cool startup that is looking for early-stage funding? If yes, we would love to hear more about it.